iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) saw a significant decrease in short interest in April. As of April 30th, there was short interest totaling 51,489 shares, a decrease of 99.1% from the April 15th total of 5,529,018 shares. Based on an average daily volume of 1,959,292 shares, the days-to-cover ratio is presently 0.0 days. Approximately 7.9% of the company’s shares are short sold.
iSpecimen Price Performance
NASDAQ:ISPC opened at $4.54 on Wednesday. iSpecimen has a 1-year low of $4.00 and a 1-year high of $127.20. The company has a 50-day moving average of $6.64 and a 200 day moving average of $13.60. The firm has a market cap of $3.37 million, a PE ratio of -0.05 and a beta of 1.75.
Institutional Trading of iSpecimen
An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC bought a new position in shares of iSpecimen Inc. (NASDAQ:ISPC – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned 0.65% of iSpecimen as of its most recent SEC filing. 13.62% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on iSpecimen
iSpecimen Company Profile
iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.
Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.
Featured Articles
- Five stocks we like better than iSpecimen
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
